Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015625
Filing Date
2021-11-12
Accepted
2021-11-12 07:00:20
Documents
60
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tril-20210930x10q.htm   iXBRL 10-Q 1560585
2 EX-10.1 tril-20210930xex10d1.htm EX-10.1 111911
3 EX-31.1 tril-20210930xex31d1.htm EX-31.1 13248
4 EX-31.2 tril-20210930xex31d2.htm EX-31.2 13274
5 EX-32.1 tril-20210930xex32d1.htm EX-32.1 10266
6 GRAPHIC tril-20210930x10q008.jpg GRAPHIC 92893
  Complete submission text file 0001558370-21-015625.txt   5766531

Data Files

Seq Description Document Type Size
7 EX-101.SCH tril-20210930.xsd EX-101.SCH 41899
8 EX-101.CAL tril-20210930_cal.xml EX-101.CAL 41669
9 EX-101.DEF tril-20210930_def.xml EX-101.DEF 165273
10 EX-101.LAB tril-20210930_lab.xml EX-101.LAB 399100
11 EX-101.PRE tril-20210930_pre.xml EX-101.PRE 296192
12 EXTRACTED XBRL INSTANCE DOCUMENT tril-20210930x10q_htm.xml XML 710124
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36596 | Film No.: 211399439
SIC: 2834 Pharmaceutical Preparations